Patients with seropositive RA on stable DMARD therapy showed a CVD risk comparable with that of the general population, unlike those whose treatment regimen was not stable.
Irrespective of age, duration of disease, and other factors, people with rheumatoid arthritis have a consistently higher risk for venous thromboembolism than the general population.